NY Bill Would Allow Low-THC Drinks in Liquor Stores

New York State Senate Bill S9220 (2025-2026), introduced February 17, 2026, by Sen. Jeremy Cooney (D-Rochester), chair of the Senate Subcommittee on Cannabis, would allow liquor and wine stores to sell low-potency cannabis beverages.

Regulatory Framework

The bill vests joint authority in the State Liquor Authority and Office of Cannabis Management over this novel class of intoxicating beverages limited to 5 milligrams of delta-9 THC per serving. Products must be maintained in a separate, distinctly marked area from alcoholic beverages, with sales confined to persons 21 years or older.

Taxation Provisions

An excise tax of 9% applies to retailers’ purchases from distributors; a 13% retail tax burdens end purchasers. Revenues from the latter are apportioned primarily to the state Cannabis Revenue Fund, approximately one-third to the locality of sale, and one-thirteenth to the liquor authority.

Legislative Precedent

This measure succeeds S8575 (the “Hemp Beverage and Taxation Act”), also sponsored by Cooney and pending in committee since November 2025, which proposes Cannabis Control Board oversight of hemp-derived cannabinoid beverages (≤5mg THC/container) with a uniform 10% tax and parallel age/labeling restrictions. As of February 19, 2026, S9220 remains referred to the Senate Investigations and Government Operations Committee.

Ohio Attorney General Files First-of-Their-Kind Antitrust Claims Against Major Multistate Cannabis Operators

By Sean P. McConnellWayne A. MackChristopher H. Casey, Paul P. JosephsonTracy GallegosMichael D. Schwamm, and James Hearon

The Ohio attorney general recently filed an unprecedented state antitrust enforcement action against nine of the nation’s largest multistate cannabis operators. The complaint alleges these defendants formed illegal cartels through reciprocal supply agreements, competitively sensitive information exchanges and discriminatory distribution practices designed to exclude independent Ohio cannabis operators from the market and artificially inflate consumer prices. The complaint seeks injunctive relief, civil forfeitures of $500 per day per defendant for each day the alleged combinations were in effect, and attorneys’ fees.

Read the full Alert on the Duane Morris LLP website.

Ohio Attorney General Files First-of-Its-Kind Antitrust Claims Against Major Cannabis MSOs

The Ohio Attorney General recently filed an unprecedented state antitrust enforcement action against nine of the nation’s largest multistate cannabis operators (MSOs). The complaint alleges these defendants formed illegal cartels through reciprocal supply agreements, competitively sensitive information exchanges, and discriminatory distribution practices designed to exclude independent Ohio cannabis operators from the market and artificially inflate consumer prices. The complaint seeks injunctive relief, civil forfeitures of $500 per day per defendant for each day the alleged combinations were in effect, and attorneys’ fees.

Key Takeaways

  • Though targeted at MSOs, this action marks a watershed moment for all cannabis and hemp businesses and the trade associations promoting their interests. Casual business arrangements that proliferate in both sectors create significant antitrust exposure.
  • This action represents the first state attorney general enforcement action targeting alleged anticompetitive conduct in the cannabis industry and follows theories advanced in private litigation currently pending in federal court in Illinois.
  • The Ohio case demonstrates state willingness to pursue enforcement theories developed in private litigation, potentially validating and lending government credibility to those claims. We can expect more antitrust enforcement activity from other states, and federal antitrust interest cannot be ruled out.
  • Cannabis and hemp companies of all sizes and their associations should take immediate steps to assess their commercial arrangements and implement robust antitrust compliance programs.

Legal Claims and Theories

The Ohio AG brings claims under Ohio’s Valentine Act (Ohio Revised Code §§ 1331.01 et seq.), alleging unlawful trusts and conspiracies against trade. The complaint identifies three primary categories of anticompetitive conduct:

Reciprocal Supply Agreements and Shelf Space Allocations. The complaint alleges that defendants entered into national “Trade Balance” agreements through which they committed to reciprocal purchasing quotas across multiple states and allocated dispensary shelf space to one another’s products. For example, corporate executives allegedly met quarterly to establish state-by-state purchasing commitments, with documented agreements showing shelf space allocations of up to 25% for competitor MSO products. The complaint alleges these arrangements were designed to exclude independent cultivators and processors from retail channels, citing internal communications describing the strategy as a “distribution game” where vendors not reciprocating purchases were eliminated.

Exchange of Competitively Sensitive Information. The complaint alleges defendants regularly shared promotional plans, pricing information, costs paid to non-MSO suppliers, and discount terms-information that would typically be closely guarded in a competitive market. According to the complaint, this information sharing facilitated coordination on pricing and allowed defendants to monitor compliance with their reciprocal dealing arrangements.

Discriminatory Supply and Promotional Terms. The complaint alleges defendants offered each other preferential pricing, including “frontload discounts,” rebates, and split co-promotion arrangements not available to independent dispensaries. These arrangements allegedly placed non-MSO dispensaries at a structural competitive disadvantage, forcing them to either maintain higher retail prices or absorb margin losses.

Practical Considerations for Cannabis and Hemp Companies and Trade Associations

From the outset, cannabis and hemp businesses have banded together to legalize cannabis and hemp. Once legalized, they have worked together to create state-specific regulatory structures. These companies have for the last decade worked together to promote their common interests in well-regulated and economically viable state markets. The informal and often collegial practices of these nascent industries that has been a strength also creates significant antitrust exposure.

All companies and associations should take action to mitigate risk:

  • Experienced legal counsel can assist by conducting privileged antitrust compliance audits of existing commercial arrangements, including supply agreements, shelf space allocations, and promotional programs across all operating states.
  • Companies and associations should consider reviewing and revising information-sharing protocols to ensure no competitively sensitive information is exchanged with competitors.
  • Companies should implement or strengthen antitrust compliance training programs for all personnel involved in purchasing, wholesale, and retail operations.
  • Companies should also work with counsel to develop document retention policies that balance legal obligations with risk management considerations.
  • Counsel can assist with coordinating regulatory and defense strategy across jurisdictions, engaging with state regulators proactively, and assessing proactive steps that may mitigate penalties or inform settlement negotiations.

If you have any questions about this Alert, please contact Paul P. Josephson, Tracy A. Gallegos, Michael D. Schwamm, James Hearon, any of the attorneys in our Cannabis Group, Sean P. McConnellWayne A. Mack, Christopher H. Casey, any of the attorneys in our Antitrust and Competition Group, any of the attorneys in our State Attorneys General Group, or the attorney in the firm with whom you are regularly in contact.

New Jersey Joins in Closing Hemp Loophole –New Legislation Regulates Hemp-Derived Products

On January 12, 2026, Governor Phil Murphy signed Senate Bill 4509 into law, ushering in a sweeping reform of New Jersey’s hemp laws and establishing a regulatory framework for intoxicating hemp products (“IHPS”) that have proliferated across the Garden State. The bill’s sponsors aimed to close a long-standing loophole created by the 2018 federal Farm Bill, which permitted IHPs to be sold widely with no oversight. The enactment of SB 4509 represents the latest and most consequential chapter in New Jersey’s multi-year effort to regulate these products.

Two years ago, New Jersey attempted to regulate IHPs but its efforts were unsuccessful. In September 2024, New Jersey enacted legislation prohibiting the sale of IHPs to minors and imposing new restrictions on their distribution. Just days before the law was scheduled to take effect, a federal judge issued a permanent injunction blocking most of its substantive provisions.  In Loki Brands LLC v. Platkin, the District Court of New Jersey held that the law’s definition of “intoxicating hemp products” expressly discriminated against out-of-state hemp by prohibiting its sale in New Jersey. The court concluded that the law violated the Dormant Commerce Clause by penalizing out-of-state producers and manufacturers. It further held that the statute conflicted with—and was, therefore, preempted by—the 2018 Farm Bill because it effectively transformed federally legal hemp into a controlled substance simply by virtue of being shipped through New Jersey.

The federal landscape concerning hemp has dramatically shifted since Loki was decided.  As part of the 2025 federal spending bill, Congress overhauled federal hemp standards by including a provision banning the sale of any hemp-derived THC product containing more than 0.3% total THC—not just delta-9 THC as permitted under the 2018 Farm Bill—on a dry weight basis.  Congress also narrowed the definition of legal hemp to exclude products containing cannabinoids that “were synthesized or manufactured outside the plant” and prohibited consumer products containing more than 0.4 milligrams of total THC per container.  Taken together, these changes render virtually all existing IHPs unlawful under federal law.  The new federal prohibition is set to go into effect on November 13, 2026. 

New Jersey’s newly enacted law is calibrated to align with these updated federal standards.  Under SB 4509,  hemp may not contain more than 0.3% total THC, including delta-8, delta-10, THCA, and similar cannabinoids, and IHPs may not contain more than 0.4 milligrams of THC per container. Products that exceed these thresholds are deemed cannabis and fall under the jurisdiction of the New Jersey Cannabis Regulatory Commission (“CRC”). As a result, the sale of such products will require a state-issued cannabis license and compliance with the same regulatory requirements imposed on licensed cannabis businesses operating in New Jersey. 

While the law took effect on January 13, 2026, its implementation will be a phased approach.  To allow the CRC time to develop its regulatory scheme, and to mitigate the economic impact on existing IHP retailers, the statute provides a grace period through April 13, 2026, during which time current sellers must liquidate their inventory.  The law does, however, carve out a narrow exception for intoxicating hemp beverages, which may continue to be sold at licensed liquor stores until November 13, 2026  when the federal prohibition goes into effect.  At that point, any beverage exceeding the new THC limits will be regulated as cannabis. 

With the passage of SB 4509, New Jersey has signaled an end to the sale of unregulated IHPs.  By harmonizing New Jersey law with federal hemp rules and addressing the constitutional defects identified in Loki, the Legislature has likely crafted a framework designed to withstand legal scrutiny while prioritizing consumer safety and regulatory clarity.

Trumps Signs Executive Order to Reschedule Cannabis: A Dramatic Shift in Federal Cannabis Policy

On December 18, 2025, President Trump signed an Executive Order to expedite the administrative process of rescheduling cannabis, marking one of the most dramatic shifts in federal cannabis policy in the past few decades.

Under current federal law, cannabis is classified as a Schedule I controlled substance—the most restrictive category of drugs.  Schedule I controlled substances are defined as having no accepted medical use and a high potential for abuse.  Schedule I substances include inherently dangerous drugs, such as heroin and LSD.

The Executive Order directs the Attorney General to expedite rescheduling cannabis from Schedule I to Schedule III.  Schedule III controlled substances are defined as having a lower potential for abuse and currently accepted medical uses, including substances such as ketamine and Tylenol with codeine. 

The rescheduling process is handled through the Drug Enforcement Agency (“DEA”) and the Department of Health and Human Services (“HHS”).  In 2022, at the direction of President Biden, DEA and HHS commenced the rescheduling process.  Both HHS and the Department of Justice issued recommendations to reschedule cannabis, but the process eventually stalled, and there has been no movement on rescheduling since January 2025 until today. 

Rescheduling cannabis to Schedule III will not only allow for medical research into cannabis, one of President Trump’s main selling points in issuing the Executive Order, but may also provide long awaited relief to cannabis operators, owners, investors, and other industry participants.

One of the most prominent and immediate benefits of rescheduling will be the removal of cannabis from the clutches of Section 280E of the Internal Revenue Code.  Section 280E disallows standard business deductions for businesses engaged in the trafficking of Schedule I or II controlled substances.  Once cannabis is rescheduled, cannabis operators will likely decrease their current tax liabilities and improve their financial viability. 

What rescheduling will NOT do is open up the door for interstate commerce and may not immediately increase the number of federally chartered banks open to banking in the industry as many are still waiting for passage of the SAFER Banking Act or similar legislation. FinCEN guidance is not impacted by the Executive Order, which means that onerous reporting and other obligations for banks will remain in place. As such, any impact to banking will likely be minimal, as banks’ compliance obligations will remain the same until such time that the SAFER Banking Act or similar legislation is passed by Congress.

The Executive Order also seeks to expand research and access to CBD products.  This comes on the heels of the funding bill passed to end the government shutdown, which included a controversial provision to close the loophole created by the 2018 Farm Bill and reclassify low-THC hemp products as controlled substances.  The ban on low-THC hemp products goes into effect in November 2026. 

While not full federal legalization, today’s Executive Order could mark the beginning of the end in draconian federal cannabis policy.  The rescheduling process will take some time, and the Executive Order could still be challenged by Congress and stake holders in the cannabis industry, but operators should remain cautiously optimistic.

Network with Duane Morris At MJBIZ Con 2025

Meet Duane Morris Partner Michael Schwamm for a networking event on Wednesday, December 3, during the MJBIZ Conference 2025. Michael will be joined by Greg Hill of BrandBirth and Rachel Wright of VERDANT Strategies for an open discussion on the current state of the industry and to share insights with cannabis professionals.

The networking event will take place from 1 p.m. to 4 p.m. at the VICE VERSA Patio Bar at the Vdara Hotel.


Webinar: Potential Cannabis Rescheduling and Its Implications in the Financial Sector

Duane Morris will hold its next Cannabis Webinar, Potential Cannabis Rescheduling and Its Implications in the Financial Sector, on Tuesday, October 21, 2025, from 1:30 p.m. to 2:30 p.m. Eastern.

REGISTER

About the Program

Players in the cannabis industry have long struggled with banking and finance issues unique to the sector. For a long time, it was next to impossible to find options for getting loans or access to banks for product-touching operations. That, thankfully, is changing. The federal government’s stated intent to reschedule cannabis and offer safe harbor protections has made more banks willing to work with the industry. Join us as we discuss recent changes to normalize financial access for cannabis companies, opportunities in fintech and how these trends can potentially stimulate significant industry growth.

Continue reading “Webinar: Potential Cannabis Rescheduling and Its Implications in the Financial Sector”

Webinar: A New Era for Immigration Policy and Enforcement – What the Cannabis Industry Needs to Know

Duane Morris will hold its next Cannabis Webinar, A New Era for Immigration Policy and Enforcement – What the Cannabis Industry Needs to Know, on Monday, October 6, 2025, from 12:30 p.m. to 1:30 p.m. Eastern.

REGISTER FOR THE WEBINAR

This year has seen many changes in the federal enforcement of immigration and employment policies, many of which have a direct effect on the cannabis industry. Termination of programs like Temporary Protected Status (TPS) and humanitarian parole, conflicting guidance from the executive and judicial branches on the scope and effective dates of those terminations, federal raids of worksites including farms, and the rapid spread of information (and misinformation) in traditional and social media on ICE enforcement efforts have all contributed to disruptions in many employers’ day-to-day operations. Our panel of attorneys will discuss the differences between now and just a year ago, and what can be expected through the remainder of this year and into the next. We will also go into detail on how to best be prepared for enforcement actions at your organization and what you can do to stay ahead of immigration policy and regulatory compliance.

Continue reading “Webinar: A New Era for Immigration Policy and Enforcement – What the Cannabis Industry Needs to Know”

© 2009- Duane Morris LLP. Duane Morris is a registered service mark of Duane Morris LLP.

The opinions expressed on this blog are those of the author and are not to be construed as legal advice.

Proudly powered by WordPress